Drugs / NPX267
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05958199 | Jul 2023 → Sep 2025 | metastatic malignant neoplasm | NextPoint Therapeutics, Inc. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPX267 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05958199 ↗ |
| Route | Intravenous | “NPX267 will be administered by intravenous infusion” NCT05958199 ↗ |